Home Job Postings Head of Cell & Gene-modified Cell Therapy R&D Center (Senior Director) This topic has replies, 0 voices, and was last updated 4 years ago by MEDIPOST. Now Editing “Head of Cell & Gene-modified Cell Therapy R&D Center (Senior Director)” Name * Password * Email Topic Title (Maximum Length 80) Company * Location Expires at We are looking for a highly motivated scientist to join our company as the Head of Cell Therapy R&D Center to lead 4 research teams developing innovative cell and gene-modified cell therapies. Reporting to the Management Board of the company, the Head of Cell Therapy R&D Center will be responsible for developments of projects from target discovery through preclinical proof-of-concept, CMC and support of early phase clinical development. Location: MEDIPOST HQ located in Pangyo, Gyeonggi-do, Korea (On-site) <strong>Primary Responsibilities</strong> • Successfully leads cell & gene-modified cell therapy discovery programs; • Provides scientific perspective and leadership for cell & gene-modified cell therapy projects of the company’s portfolio through collaboration with other internal departments such as Regulatory Affairs and GMP Manufacturing Facility; • Effectively applies best practices to improve operational efficiency; • Lead teams of scientists to build cell and gene-modified cell therapy pipelines; • Works with leadership team to meet corporate goals. <strong>Qualification</strong> • PhD with 10+ years of relevant post-doctoral and/or industry experience in cell and/or molecular biology or related field, including 5+ years of relevant experience in managing research teams in a biotech or pharmaceutical R&D environment; • In-depth knowledge and hands-on experiences in pre-clinical studies, CMC studies of cell and/or gene-modified cell therapies are required; • Strong publication records and presentation skills are preferred; • Strong communication skills and team work ethics are required; • Capability to translate strategy into action, to successfully manage projects and timelines, organize/track complex information, and prioritize accordingly; • Extensive experiences in managing collaborations. Contact: Sophia Yang – sophia.yang@medipostamerica.com <strong>About MEDIPOST</strong> MEDIPOST is a Korean company founded in 2000 and became a public company in 2005, listed on KOSDAQ with 300+ current employees. MEDIPOST operates 2 overseas subsidiary companies in Tokyo, Japan and Gaithersburg MD, U.S. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)”. To date, over 20,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. CARTISTEM® has also successfully completed the Phase I/II trial in the U.S. and the Phase III trial is planned to commence in 2022. CARTISTEM® is currently undergoing Phase III clinical trial in Japan, while BLA marketing-authorization is under review in Malaysia. PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. Longer term (3, 4 and 5 year) follow-up on premature infants born with high-risk of developing BPD who received PNEUMOSTEM® demonstrated significant benefit with regards to cognitive development compared to cohort of premature infants who received standard-care alone. PNEUMOSTEM® has received Orphan Drug Designation (ODD) and the Fast-Track Designation (FTD) by the US-FDA and ODD by the EMA. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA). SMUP-IA-01 has completed dosing of all 12 subjects in the first-in-human Phase 1 clinical trial in Korea and the 12-months follow-up data demonstrated significant and sustained improvement in subjective pain and knee function assessments in all subjects, with longer-term follow-up planned. Phase 2 randomized controlled trial in Korea will commence in 2022. SMUP platform is MEDIPOST’s proprietary, patent-protected cell selection and expansion technology using allogeneic umbilical cord blood-derived stem cells as a therapeutic modality. We are looking for qualified and experienced scientists to embark on the exciting journey of developing innovative cell and gene-modified cell therapy programs for unmet medical needs at MEDIPOST. www.medi-post.com KOSDAQ ticker: 078160 I agree to the terms of service Update List
